The antiangiogenic activities of ethanolic crude extracts of four Salvia species by Malek Zihlif et al.
Zihlif et al. BMC Complementary and Alternative Medicine 2013, 13:358
http://www.biomedcentral.com/1472-6882/13/358RESEARCH ARTICLE Open AccessThe antiangiogenic activities of ethanolic crude
extracts of four Salvia species
Malek Zihlif1*, Fatma Afifi2, Rana Abu-Dahab2, Amin Malik Shah Abdul Majid3*, Hamza Somrain1, Mohanad M Saleh1,
Zeyad D Nassar3,4 and Randa Naffa5Abstract
Background: Angiogenesis is one of cancer hallmarks that are required for both cancer progression and metastasis.
In this study we examined the antiangiogenic properties of the ethanolic crude extracts of four Salvia species
grown in Jordan.
Methods: The direct antiangiogenic activity was evaluated using various models: ex vivo rat aortic ring assay,
in vitro assessment of HUVEC proliferation and migration, and in vivo CAM assay, while we used the changes in the
expression of HIF-1α and VEGF in breast cancer cells (MCF 7) as an indicative for the indirect antiangiogenic activity.
Results: All four crude extracts showed a potential antiangiogenic activity in the rat aortic assay, however two
species were found to be cytotoxic against Fibroblast cell line (PLF); the finding that caused the exclusion of these
two extracts from further studies. Of the two remaining extracts, S. triloba showed very promising direct and
indirect antiangiogenic activities. S. triloba inhibited the HUVEC proliferation with an IC50 of 90 μg/mL and HUVEC
migration by 82% at 150 μg/mL. Furthermore, the in vivo CAM assay also illustrated the high impact of S. triloba
against the newly formed vessel in the chicken embryonic membrane. Interestingly, the S. triloba inhibited the
expression of VEGF at the mRNA and protein and the HIF-1α mRNA in the MCF 7 breast cancer cells under both
normoxic and hypoxic conditions.
Conclusions: Taken together, all these findings of the direct and indirect angiogenic investigations nominated
S. triloba as a highly potent antiangiogenic plant that may have chemotherapeutic and/or chemoprevention potentials.
Keywords: Salvia triloba, Salvia hormium, Salvia dominica, Salvia syriaca, Antiangiogenesis, MCF 7, JordanBackground
Angiogenesis is the formation of new blood vessels. Cancer
is angiogenesis dependent; any significant increment in
tumour size must be in synchrony with increment in
the blood supply. The new blood vessels supply the
tumour cells with extra amount of oxygen and nutrients,
and most importantly they facilitate cancer cell metastasis
to other localities [1]. All solid tumours are dependent
on the angiogenesis for tumour growth and metastasise
[2]. Breast cancer is the most common cancer in women
counting for approximately 27% of all new cancers [3].
It is characterized by a distinct metastatic pattern [4].* Correspondence: M.zihlif@ju.edu.jo; aminmalikshah@gmail.com
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reproduction in any medium, provided the orCancer cells within the tumour use the newly formed
blood vessels as a port to metastasize to other localities
[5]. Although less than 0.05% of circulating tumour cells
has a potential to become stable metastases [6], the vast
majority of breast cancer-related deaths result from
metastatic tumours [7]. Angiogenesis, one of cancer hall-
marks is involved in the progression and metastasis of
breast cancer [8]. The process is tightly controlled through
a balance of positive and negative regulatory factors
and is triggered by pro-angiogenic growth factors [9].
Vascular endothelial growth factor (VEGF) is a major
mediator of angiogenesis in cancer [10]. VEGF expression
is induced under hypoxic conditions; a multistage process,
in which the alpha subunit of hypoxia inducible factor-1
(HIF-1α) plays an important role [10]. Under normoxic
condition, HIF-1α rapidly decreases since it is bound to the
tumour suppressor Von Hippel-Lindau (VHL) protein,d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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becomes a target for the proteosome. However, the low
blood supplies toward the tumour mass drives the
tumour tissue into hypoxia, which may induce transcrip-
tional activation of VEGF expression through HIF-1α
stabilization [11]. Since angiogenesis plays a prominent
role in tumour growth and metastasis, inhibition of
angiogenesis is considered as an important strategy for
cancer therapy [12]. Furthermore, inhibiting angiogen-
esis before it starts, which known as angioprevention,
has the potential to block the expansion of hyperplastic
foci and subsequent tumour development at the prema-
lignant stage [13]. Angioprevention compounds work
through diverse pathways, amongst those is the interference
with expression of the VEGF and HIF-1α, which stand out
among the diverse factors that drive angiogenesis [13].
The genus Salvia is the largest and the most important
genus of the family Lamiaceae. This genus has about 900
species, widespread throughout the world, and includes
several ornamental, culinary and medicinal species [14].
Nineteen species of Salvia are reported to occur in the flora
of Jordan [15]. Published data indicated that many Salvia
species exert diverse biological activities, and have been used
in many parts of the world as part of the local traditional
medicines to treat various conditions. Examples of phar-
macological properties are antioxidant [16], antimicrobial
[17], anti-inflammatory, analgesic [18], antipyretic, hemo-
static [19], hypoglycemic [20] and anti-tumour [21] activities.
S. miltiorrhiza Bunge, commonly used in traditional Chinese
herbal medicine to treat cardiovascular and hepatic dis-
orders, has been shown recently to have significant anti-
tumour and anti-angiogenesis properties [22]. Interestingly,
the same plant, S. miltiorrhiza, has demonstrated some pro-
antiangiogenic activity. Another recent publication has also
reported antiangiogenic activity for S. officinalis [23].
Encouraged from the promising results of S. officinalis,
the current study was designed to evaluate the antiangio-
genic activity of four Salvia species grown in Jordan. Etha-
nolic crude extracts of the leaves of S. dominica, S. syriaca,
S. triloba and S. hormium were prepared and their direct
antiangiogenic properties were investigated using rat aortic
ring assay. Plant extracts that exhibited direct antiangio-
genic activities, were further explored for their direct activ-
ity in human umbilical endothelial cells (HUVEC)
cytotoxicity assay, migration assay and chicken embryo
chorioallantoic membrane (CAM) assay. Moreover, to test
the extracts’ indirect antiangiogenic activity, the effect on
the expression of the VEGF protein and expression of both,
VEGF and HIF-1α mRNA was examined using MCF 7
breast cancer cell line. All extracts were phytochemically
screened using thin layer chromatography (TLC) and the
presence of detected classes of secondary metabolites was
reported. The effects of the extracts on normal cells were
tested using periodontal fibroblast cell line (PLF).Methods
Plant samples collection and extraction
Plant samples were collected during early flowering period
(spring/summer 2009) from different areas in Jordan and
have been identified by Prof. Dr. Barakat Abu Iremaileh
(Faculty of Agriculture, The University of Jordan). Voucher
specimens were deposited at the Department of Pharma-
ceutical Sciences, Faculty of Pharmacy, The University of
Jordan. Plant samples were cleaned from extraneous material
and dried at room temperature. Each 2.5 g of coarsely pow-
dered plant material was extracted by refluxing with 25 mL
70% ethanol for 30 min and kept overnight at room
temperature before filtration. After filtration, ethanol was
evaporated until dryness and the crude extracts were weighed.
The crude extracts were dissolved in dimethyl sulphoxide
(DMSO) to a final stock concentration of 10 mg/mL. All ex-
tracts were kept at 4°C until the time of experiment.
Cell lines and cell culture
The human breast adenocarcinoma (MCF 7) was pur-
chased from the European Collection of Animal Cell
Culture (ECACC). Fibroblast cell line provided kindly
from the Faculty of Dentistry, Jordan University of Science
and Technology. Human umbilical vein endothelial cell
line (HUVEC) was purchased from American Type Cell
Culture Collection (ATCC). The MCF 7 and fibroblast cell
lines were cultured in DMEM/F12 and DMEM medium
(Gibco, Invitrogen, USA), respectively. Media were supple-
mented with 10% fetal bovine serum (FBS) (Gibco, Invi-
trogen, USA), 1% of 2 mM L-glutamine, 50 IU/mL
penicillin and 50 μg/mL streptomycin (Lonza, Belgium).
HUVECs were cultured in F12K medium (Gibco, Invi-
trogen, USA) supplemented with 0.1 g/mL Heparin
(Sigma, USA) and 1% EGFR (Sigma, USA) 10% FBS, 1%
of 2 mM L-glutamine, 50 IU/mL penicillin and 50 μg/mL
streptomycin. HUVECs from passages 2 through 4 were
used through this study. All cells were maintained at 37°C,
5% CO2 in a humidified incubator.
Rat aortic ring assay
The rat aortic ring assay experiment was conducted after
the experimental procedures were revised and approved
by the Animal Ethics Committee of The University of
Jordan. The assay was performed according to the standard
protocol of Brown et al. [24], with minor modifications.
Twelve to fourteen weeks old Sprague Dawley male rats
were obtained from the animal house facility of the
Faculty of medicine, The University of Jordan (UJ). The
animals were humanely sacrificed via cervical disloca-
tion under anesthesia with diethyl ether. Thoracic aorta
was excised, rinsed with serum free media, cleaned from
the fibroadipose tissue and was cross sectioned into
thin rings of 1 mm thickness. M199 basal medium
(Gibco, Invitrogen, USA) was used for the lower layer
Zihlif et al. BMC Complementary and Alternative Medicine 2013, 13:358 Page 3 of 10
http://www.biomedcentral.com/1472-6882/13/358after adding fibrinogen and aprotinin (Sigma, USA) at
3 mg/mL and 5 μg/mL, respectively. A 300 μl of M199
medium was loaded in each 48-well plate and one aortic
ring was seeded in each well. To each well, 10 μl of throm-
bin (Sigma, USA); prepared at 50 NIH U/mL in 0.15 M
NaCl: bovine serum albumin (1%); was added and then was
allowed to solidify at 37°C in 5% CO2 for 60–90 min. The
top layer medium was prepared by adding the following
to M199 basal medium: 20% of heat inactivated fetal
bovine serum (HIFBS) (Gibco, Invitrogen, USA), 1% L-
glutamine (Lonza, Belgium), 0.1% aminocaproic acid
(Sigma, USA), 1% amphotericin B (Lonza, Belgium)
and 0.6% gentamicin (Lonza, Belgium). Plant extracts
were added to the top layer medium at concentration of
100 μg/mL. The tissue rings were incubated at 37°C, 5%
CO2 in a humidified incubator. On day 4, the top layer
medium was changed with fresh medium prepared as pre-
viously mentioned. The DMSO (1% v/v) and Suramin
(100 μg/mL) were used as negative and positive controls
respectively. The results examined microscopically at ap-
propriate magnification and the magnitude of blood ves-
sel outgrowth was quantified using Leica Quin software
package [25], according to the technique developed by
Nicosia et al. [26]. The results are presented as mean per-
cent inhibition to the negative control ± SD, (n = 3).
In vitro cytotoxicity assay
Plant extracts were tested for cytotoxicity against fibro-
blast cell line. Cells were seeded at density of 10,000 cells/
well in 96-well plates. Afterwards, the cells were treated
with two concentrations; 50 and 100 μg/mL in quadricate.
Control wells contained DMSO at same concentrations.
After 72 h incubation, cell viability was determined by
MTT assay according to cell proliferation assay kit
(Promega, USA). Absorbance (OD) was measured at
570 nm with background subtraction at 630 nm.
Antiproliferative activity
HUVECs were seeded at a density of 10 × 103 cells/well
in 96-well plates and allowed to attach overnight. Plant
extracts that showed antiangiogenic activity with aortic
ring assay were screened on HUVECs for their IC50.
Cells were treated with different concentrations (1.5-
100 μg/mL) in quadricate. After 72 h treatment, MTT
assay was performed according to cell proliferation assay
kit (Promega, USA). Absorbance (OD) was measured at
570 nm with background subtraction at 630 nm. The
calculation of IC50 was performed using a sigmoidal
plotting function provided in the GraphPad Prism soft-
ware. DMSO was used as a negative control.
Wound healing migration assay
The migration assay was carried out as described previ-
ously [27]. Briefly, HUVECs were seeded at 5 × 105/well in6-well plates and allowed to form a confluent monolayer.
The layer of cells was then scraped with a 20–200 μl
micropipette tip to create a wound of ~1 mm width. Cells
were then washed twice with PBS and replaced with
medium containing 100 AND 150 μg/mL of the plant ex-
tracts. The wounds were photographed at 0, 12 and 18 h,
and the number of migrated cells was counted. Ten
readings per well were taken. The results are presented as
mean percentage of migration inhibition to the control
± SD, (n = 3).
In vivo CAM assay
Antiangiogenic effect of the plant extracts was investigated
in vivo using CAM assay as mentioned previously [28].
Five day-old fertilized eggs were obtained from local
hatchery. 5 mL of albumin was aspirated and the eggs
were incubated horizontally to allow the CAM to detach
from the shell. Chosen extracts were prepared in 1.2%
agarose discs at concentration of 100 μg/disc. Discs con-
taining the vehicle only (DMSO) were used as negative
control. A small window opening was made in the shell,
and the discs were directly applied onto the CAM. The
square opening was covered with sterilized surgical tape
and the embryos were incubated for 48 h at 37°C. The
CAMs were photographed under a dissecting microscope
and blood vessels in each CAM were counted. The results
are presented as a mean percentage of inhibition to the
control ± SD, (n = 3).
Expression of VEGF and HIF-1α
MCF 7 cells treatment
MCF 7 cells were seeded at a concentration of 3 × 106
cells in T75 Flask on the day before treatment. Then, the
medium was replaced with a new medium, containing
three concentrations of plant extract 100, 200 and
300 μg/mL. The cells were incubated at 37°C, 5% CO2 for
16 h, under two conditions; hypoxic (0.1% O2) and nor-
moxic conditions (20% O2). However, before cells were ex-
posed to the hypoxic condition, they were treated under
normoxic condition for 1 h then maintained under hyp-
oxic conditions for 16 h. Hypoxic condition was per-
formed by incubating the cells in GasPak Pouch (Becton
Dickinson, Sparks, Md., USA). DMSO with the same con-
centrations as the extracts were then used as negative con-
trols. Then, cells were harvested for RNA extraction.
RNA extraction and cDNA synthesis
Total RNA was extracted using Trizol, LS (Invitrogen,
USA). The RNA quality was assessed by spectrophotomet-
ric method (A260/A280). RNA samples were stored at −80°C
until used. Complementary DNA (cDNA) was synthesized
from 1.0 μg total RNA using RT-PCR Kit (Promega, USA)
in a final volume of 20 μl using random primers according
to the manufacturer's instructions.
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Q-PCR was carried out in IQ4 real time PCR (BioRad,
USA). The reaction mixture consisted of 1X GoTaq qPCR
Master Mix (12.5 μl) (Promega, USA), 2.5 μl primers and
1.0 μl of cDNA in a total volume of 25 μl. VEGF and
HIF-1α QuantiTect Sybr green primers were purchased
from Qiagen, Germany. GAPDH was used as internal
reference control. GAPDH primers (Invitrogen, USA)
sequences used in this study were as previously mentioned
[29]. The PCR condition for GAPDH, VEGF and HIF-1α
comprised of first incubation at 95°C for 15 min, 40 cycles
of denaturation at 95°C for 15 sec, annealing at 55°C
for 30 sec, extension at 72°C for 30 sec. Fluorescence
was recorded at the end of extension. A negative control
without cDNA template was run simultaneously with
every assay. To generate a standard curve, template
cDNA from untreated-control MCF 7 cells was used.
Quantification of gene expression was calculated by the
standard curve and cycle threshold of each sample. The
results of genes expression were normalized to reference
gene expression and the fold exchange was determined in
comparing with untreated cell control. Two replicates of
this experiment were carried out, in which every gene
had a duplicated reading. A melt curve analysis was done
after QPCR to ensure the specificity of PCR product.Determination of VEGF protein level
MCF 7 cells were seeded in a 96-well plate at a density of
1 × 105cells/well and incubated overnight. Cells were
cultured in a serum free medium for 2 h and then replaced
with 10% FBS medium in presence of various doses of
plant extracts at 100, 200, 300 μg/mL concentrations for
48 h under normoxic and hypoxic conditions. control
wells were treated with DMSO Hypoxic condition were
performed by incubating the cells in GasPak Pouch
(Becton Dickinson, Sparks, Md., USA). Each concentration
was prepared in triplicates. The negative control used was
DMSO, with the same concentrations of the extracts.
Media from each well was collected and stored at −20°C
until tested. VEGF concentrations in the conditioned
media were quantified by Quantikine Human VEGF
ELISA kit (R&D Systems, Minneapolis, USA) according
to the manufacturer’s protocol. MTT assay was used
for correcting the amount of VEGF produced to the
number of viable cells.Statistical analysis
Results were presented as means ± SD. The differences
between groups were compared by the one way ANOVA
followed by Tukey Post-hoc test and considered signifi-
cant at P < 0.05. The statistical analysis was carried out
by using SSPS edition 16.0.Results
Rat aortic ring assay
In order to evaluate the antiangiogenic properties of the
plant extracts, we performed the rat aortic ring assay at
two concentrations: 50 and 100 μg/mL (Figure 1). All of
the 4 Salvia ethanolic extracts exhibited high inhibitory
activity when tested at 100 μg/mL; they resulted in more
than 70% of the mean percent inhibition to the vehicle
(P < 0.05) (Table 1). Interestingly, at 50 μg/mL, the four
extracts demonstrated different behavior. S. dominica and
S. syriaca continued to show the highest inhibitory effects
(Table 1 and Figure 1). While, S. hormium failed to keep
any inhibitory activity at this concentration (P > 0.05)
(Table 1 and Figure 1). S. triloba succeed in keeping its
inhibitory activity and scored 77.67 ± 5.97% vessel out-
growth inhibition (P < 0.05) (Table 1 and Figure 1).
In vitro cytotoxicity assay
To assess the cytotoxicity effects of the four Salvia extracts
on normal cells, we tested the effect of those extracts at
100 μg/mL on the proliferation of periodontal ligament
fibroblasts cells (PLF) in culture. As indicated in Table 1,
S. dominica and S. syriaca exhibited clear cytotoxic effects
by reducing the cells viability to less than 25% (P < 0.05).
On the other hand, S. triloba and S. hormium showed
no or negligible inhibitory effect on PLF cell proliferation
(P > 0.05).
Antiproliferative activity against HUVECs
In order to confirm the direct antiangiogenic activity
which is demonstrated in the rat aortic assay, the effects
of the non-toxic extracts on PLF cells on two of HUVEC
functions (proliferation and migration) were evaluated.
In HUVEC proliferation assay, S. triloba and S. hormium
exhibited IC50 of 90.0 ± 0.4 and 121.0 ± 3.5 μg/mL, respect-
ively. The antiproliferative effect of these plant extracts on
HUVECs did not result from a cytotoxic effect, because 90,
111% of the endothelial cells were alive at 50 μg/mL
concentration after 72 h treatment, respectively.
Wound healing migration assay
The scratch wound healing assay was performed to
evaluate the effect of S. triloba and S. hormium extracts
on HUVEC migration. Wound repair by endothelial cells
was observed in untreated control wells. In contrast,
inhibition of migration was clearly observed in wells
with S. triloba at 100 μg/mL and 150 μg/mL concentra-
tion after 18 h incubation with 55.6 ± 5.2% (P = 0.000) and
80.6 ± 3.9% (P = 0.000) inhibition, respectively (Figure 2).
While S. hormium at 100 μg/mL showed insignificant
inhibition at 100 μg/mL with 6.48 ± 3.9% (P >0.05), and
a modest inhibition at 150 μg/mL concentration with
23.2 ± 2.5% compared to controls (P =0.001) (Figure 2).
Figure 1 Effect of selected plant extracts on rat aortic vessel
outgrowth. (A) negative control (B) positive control (Suramine)
(C, D) 50 and 100 μg/mL of S. dominica (E, F) 50 and 100 μg/mL of S.
hormium, (G, H) 50 and 100 μg/mL of S. triloba and 50 and 100 μg/mL
of S. syriaca (I, J).
Table 1 Column 1: list of the plant extracts
Plant
name
Aortic assay Aortic assay PFL cells
% of inhibition % of inhibition % viability
(100 μg /mL) (50 μg /mL) (100 μg /mL)
S. syriaca 100.0 ± 0.0 100.0 ± 0.0 20.2 ± 1.6
(P = 0.000) (P = 0.000) (P = 0.000)
S. dominica 100.0 ± 0.0 84.1 ± 5.4 13.8 ± 7.9
(P = 0.000) (P = 0.000) (P = 0.000)
S. hormium 77.1 ± 6.8 3.1 ± 1.2 111.7 ± 2.0
(P = 0.000) (P = 0.995) (P = 0.000)
S. triloba 97.1 ± 0.8 77.76 ± 5.96 90.0 ± 3.7
(P = 0.000) (P = 0.000) (P = 0.902)
Column 2 and 3: show the rat aorta ring assay results as a mean percent
inhibition to the vehicle (DMSO) ± S.D at two concentrations of 50 and 100 μg/
mL. Column 4: show the cytotoxic effect of the plant extracts on the
proliferation of PFL cells at 100 μg/mL.
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In vivo antiangiogenic effect of S. triloba and S. hormium
were also tested using CAM assay as an in vivo model
at a dose of 100 μg/mL. As shown in Figure 3, a clearinhibitory activity for the S. triloba extract with 49.1 ± 4.1%
(P = 0.001) inhibition was observed, while S. hormium ex-
tract showed insignificant inhibition 20 ± 5.3% (P >0.005).
Q-PCR for VEGF and HIF-1α expression after
S. triloba treatment
Two steps RT-QPCR were used to evaluate VEGF and
HIF-1α mRNA expression in MCF 7 cells after the treat-
ment with S. triloba extract. As shown in Figure 4, the S.
triloba extract showed a significant down-regulatory effect
on the expression of HIF-1αmRNA at the 3 concentrations
(100 μg/mL, 200 μg/mL and 300 μg/mL) under normoxic
and at 200 and 300 μg/mL under hypoxic conditions
(P < 0.05). This inhibitory activity reached the maximum
at the 300 μg/mL (P = 0.00), where the HIF-1α mRNA
expressions were down-regulated approximately 4 and 2.5
fold at the normoxic and hypoxic conditions, respectively.
On the VEGF side, the inhibition of the expression was
only observed at the 300 μg/mL under both the normoxic
and the hypoxic conditions (P < 0.05).
Decreased levels of VEGF protein expression in MCF 7
cells after S. triloba treatment
As shown in Figure 5, the S. triloba extract was very ef-
fective in reducing the protein level under both, hypoxic
and normoxic conditions in a dose dependent manner.
Interestingly, the S. triloba extract decreased the VEGF
protein level using 1, 2, 3 times IC50 concentration (90,
180, 270 μg/mL) by 15.4% (P =0.266), 89.3% (P =0.000)
and 97.4% (P =0.000) under normoxic conditions and by
31.9% (P = 0.000) 84.5% (P =0.000) and 90.2% (P =0.000)
of inhibition under hypoxic conditions.
Thin layer chromatography (TLC) of the extracts
All four plants showed the presence of terpenoids and
flavonoids. Using preparative TLC techniques and in
Figure 2 Effects of S. triloba and S. hormium on HUVEC migration. A scratch is created and then cells were treated with or 100 and
150 μg/mL of plant extract for 18 h. The graph represents the number of migrated cells after 18 hours treatment for the two extracts at two
concentrations. *P < 0.05.
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tile oils components identified were alpha terpineol and
1,8- cineol and the major flavonoid traced was quercetin.
Discussion
Angiogenesis is an essential step in solid tumour develop-
ment, invasion, and metastasis. The antiangiogenesis strat-
egy has been postulated for prevention and treatment
of breast cancers [30]. There are two accepted ways to
modulate angiogenesis, namely direct and indirect
pathways. The direct way depends on modulating the
vascular endothelial cells ability to proliferate, migrate
and respond to angiogenic proteins such as VEGF. The
indirect way is based on the ability to alter the expression
as well as to change the activity of angiogenic proteins
that activate angiogenesis. This also includes regulating
the expression of the receptors on endothelial cells [31].
In the present study, the angiogenic activity of the crude
ethanol extracts of four Salvia species grown in Jordan
(S. dominica, S. syriaca, S. triloba and S. hormium) has
been investigated.Starting from the direct angiogenic findings, all four
extracts have significantly inhibited the formation of new
blood vessels in the rat aortic assay at 100 μg/mL. Interest-
ingly, the reduction in the concentration to 50 μg/mL for
the four extracts revealed different behavior. S. dominica,
S. syriaca, S. triloba extracts continued to show a signifi-
cant inhibitory activity (P < 0.05), while S. hormium failed
to show any inhibitory activity (P > 0.05). To test whether
this activity is a selective antiangiogenic or a result of a
direct cytotoxic activity, the anti-PLF proliferative test at
100 μg/mL was performed. The results indicated that S.
dominica and S. syriaca have significant cytotoxic effects
(P = 0.000). These observations clearly point out that
the strong inhibitory activity of S. dominica and S. syriaca
belongs to their strong cytotoxic effects rather than their
selective antiangiogenic actions. Based on these findings,
these two extracts were excluded from further experi-
ments and emphasis was given on the non-toxic extracts,
S. triloba and S. hormium.
The direct antiangiogenic activity of the two extracts
of S. triloba and S. hormium were tested further on two
Figure 3 Effect of S. triloba and S. hormium on neovascularization
in CAM assay. The embryos were treated for 24 h with (A) 1%
DMSO as negative control, (B) S. hormium 100 μg/mL and (C)
S. triloba 100 μg/mL.
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and endothelial cell migration. These two assays repre-
sent two major steps in angiogenesis process. The anti-
HUVEC proliferation results showed that the IC50 value
of S. triloba and S. hormium are 90 ± 0.36 and 121 ±
3.47 μg/mL, respectively. The obtained IC50 indicated that
the two extracts do possess a direct anti-proliferation
activity against the HUVECs. The values also point outthat the two extracts do not have a direct cytotoxic
activity against HUVECs as the two IC50 values are far
from the 20 μg/mL; the IC50 that has been chosen as
an indication of a direct toxic activity of the plant
extracts [32]. Interestingly, the results of migration assay
of both extracts illustrated that S. triloba inhibits signi-
ficantly HUVEC migration in concentration-dependent
manner, while S. hormium showed significant inhibitory
activity only at the highest concentrations (P = 0.000). The
final step in the direct angiogenesis investigation was to
test for antiangiogenic activity in vivo. The vascularization
in chick embryo was chosen as an in vivo model. Again,
the highly significant ability of inhibiting the formation of
new blood vessels by S. triloba were obvious (P = 0.001),
the finding that enforced the in vitro observation and
voted for the high potential of S. triloba as inhibitor of
many crucial steps of the angiogenesis process.
As to the indirect angiogenic activity, the investigation
was limited to S. triloba, where we assessed the effect of
ethanolic extracts of S. triloba on VEGF and HIF-1α
mRNA and VEGF protein expression under normoxic and
hypoxic conditions. The protein expression measurement
was limited on the VEGF because it is the principle medi-
ator of tumour angiogenesis [33]. The mRNA and protein
expression measurements were conducted at two condi-
tions, the normoxic and hypoxic conditions. The hypoxic
environment was adapted to resemble the in vivo tumour
conditions, in which the VEGF expression is known to be
elevated [34,35]. Interestingly, S. triloba demonstrated a
significant inhibitory activity on expression of the VEGF
and HIF-1 α mRNA, and also on the protein expression of
VEGF under normoxic and hypoxic conditions (P < 0.05).
Interestingly, in comparison with normoxic condition, the
hypoxic condition up-regulate the VEGF protein expres-
sion 1.5 times, and S. triloba illustrated a high potency in
reversing this over-expression. Combining these indirect
angiogenic findings with the fact that VEGF is one of the
major HIF-1 targeted genes, specifically in recruiting the
endothelial cells into hypoxic and vascular areas does point
that the alteration in expression the of VEGF mRNA and
protein by S. triloba may resulted from modulating the
HIF-1 expression [10].
Taken the direct and indirect antiangiogenic investiga-
tions on crude ethanol extracts of four Salvia species, S.
triloba can be nominated as a potent antiangiogenic plant
that may have chemotherapeutic and/or chemoprevention
potentials. Chemoprevention potentials are summarized
by its direct antiangiogenic ability via the inhibition of
the endothelial cell proliferation and its indirect antian-
giogenic ability through inhibiting the VEGF expression.
Since VEGF ligand may affect tumour vasculature in early
tumour development through the recruitment of bone-
marrow–derived progenitor cells that form the building
blocks of a new vascular network [35], it is tempting to
Figure 4 The effect of S. triloba on VEGF and HIF-α mRNA expression after 16 h treatment at normoxic and hypoxic conditions.
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here might contribute to its angiopreventive effect. VEGF
also work throughout tumour development, in which
it helps existing vasculature survive, hence permitting
tumours to sustain their requirements over their entire life
cycle. Furthermore, the chemotherapeutic potential of
S. triloba was noticed through significant inhibitory activity
of this plant against HIF-1α mRNA expression, which
is a master transcription factor related to cell proliferation/
survival and resistance to chemotherapy and radiation [34].
Importantly, HIF-1α antisense therapy demonstrated a
synergistic anti-tumour effect with immunotherapy [36].
Moreover, the angioprevention activity can also be specu-
lated building on the significant inhibitory activity of S.
triloba against HIF-1α mRNA expression. HIF-1α is one
of the most important transcription factors that operate to
sense environmental clues that drives angiogenesis [13].
Importantly, Hao et al. (2011) showed that RNAi targeting
HIF-1α is effectively inhibiting the progression of oral
squamous cell carcinoma and concluded that it may be
used as a potent and specific therapy for oral cancer,
especially in inhibiting and preventing cancer cell angio-
genesis and survival [37].Figure 5 The effect of S. triloba on VEGF protein expression after 48 hOn the other hand, the chemoprevention values perhaps
will be more convincing by knowing that this plant is
very popular in the Middle East, especially in the Arabic
countries such as Jordan and Palestine [38,39], where
people consume S. triloba on daily basis, either by drink-
ing it alone or using it as a flavoring agent to black tea.
Further studies are needed to include S. triloba to the list
of dietary phytochemicals for which chemopreventive
activities by interfering with multiple signaling pathways
aberrant in cancer have been demonstrated [40-43].
Conclusion
Out of the four crude ethanol extracts of four Salvia
species grown in Jordan (S. dominica, S. syriaca, S. triloba
and S. hormium). S. triloba has shown a potent direct and
indirect antiangiogenic activity that may have chemother-
apeutic and/or chemoprevention potentials. The direct
antiangiogenic activity were proven using the rat aortic
assay, The anti-HUVEC proliferation, migration assay
and CAM assay. The indirect antiangiogenic activity were
proven through assessing the effect on VEGF and HIF-1α
mRNA and VEGF protein expression under normoxic
and hypoxic conditions.treatment at normoxic and hypoxic conditions.
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